These findings suggest that ACOD1 is a potential target for immune-oncology drugs, and that IRG1-deficient macrophages represent a promising cell therapy strategy for cancer treatment, even in pancreatic tumors that are resistant to T cell-based immunotherapy (Fig. 3). The gene discussed is ACOD1; the disease is cancer.